Gilead remdesivir results mixed in moderate COVID-19 patients

Gilead Sciences Inc said on Monday its antiviral drug remdesivir had mixed results in a late stage study of people with moderate COVID-19, as patients given a five-day course of the treatment showed statistically significant improvement, while those given it for 10-days did not.